New shot for hepatitis b heads into early safety testing

NCT ID NCT07600788

Recruiting now Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This early-stage study tests a single injection of AHB-137 in 32 people with chronic hepatitis B, some with mild to moderate liver dysfunction and some with normal liver function. Researchers will measure how the drug moves through the body and check for safety issues. The goal is to understand how liver problems affect the drug, not yet to see if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AHB-137 injection
What this could lead to: If successful, this could help determine safe dosing for people with liver problems, moving toward a treatment for chronic hepatitis B.
What could go wrong: This is a very early Phase 1 study with only 32 participants, focused on safety and drug levels, not effectiveness. It may not lead to a working treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AusperBio Investigational Site
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, China

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Zhengzhou, Henan, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Chengdu, Sichuan, China

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Huashan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.